European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) guidelines for AR recommend AIT for patients with uncontrolled moderate-to-severe symptoms of AR, with or without conjunctivitis, on exposure to clinically relevant allergens, and confirmation of IgE sensitization to clinically relevant allergens (via SPT or serum-specific IgE), and inadequate control of symptoms despite reliever medication and allergen avoidance measures, and/or unacceptable adverse effects of medication [42]. The gene discussed is IGHE; the disease is conjunctivitis.